fda bpc-157 compounding category 2 list Spoke with @gohealio about the FDA's newly announced Pharmacy Advisory Committee, which meets later this month to review seven peptides including and TB-500. We discussed committee composition, timelines, and what FDA Briefing Document Pharmacy Compounding

What we know is, here in the state of Massachusetts, 0.002 percent of fully vaccinated individuals have experienced severe disease

Jimnez-Jimnez FJ, Molina JA, Hernnz A, et al

DOI: 11

What insurance typically covers FDA-approved peptides for approved indications: Semaglutide (Ozempic) for type 2 diabetes: Often covered Semaglutide (Wegovy) for obesity: Sometimes covered with restrictions Tirzepatide (Mounjaro) for type 2 diabetes: Often covered Tirzepatide (Zepbound) for obesity: Limited coverage What coverage looks like: Prior authorization typically required Documentation of failed dietary interventions BMI thresholds for weight loss indications Co-pays still substantial ($100-500 monthly) What insurance doesn't cover The vast majority of peptide therapy falls outside insurance coverage: Compounded peptides (BPC-157, TB-500, most growth hormone peptides) Anti-aging applications even for FDA-approved drugs Performance enhancement uses Off-label applications These costs are entirely out-of-pocket for most patients

Lifestyle changes include consuming foods high in vitamin B12, such as meat, fish, eggs, and dairy